Randomized controlled trial of fish oil and montelukast and their combination on airway inflammation and hyperpnea-induced bronchoconstriction

• Published in: PloS one 2010-10, Vol.5 (10), p.e13487
• Main Authors: Tecklenburg-Lund, Sandra, Mickleborough, Timothy D, Turner, Louise A, Fly, Alyce D, Stager, Joel M, Montgomery, Gregory S
• Format: Article
• Language: English
• Subjects: Acetates - administration & dosage; Acetates - therapeutic use; Adolescent; Adult; Airway management; Analysis; Anti-Asthmatic Agents - administration & dosage; Anti-Asthmatic Agents - therapeutic use; Asthma; Biochemistry; Biomarkers; Blindness; Breath Tests; Bronchitis - drug therapy; Bronchitis - physiopathology; Bronchoconstriction; Bronchoconstriction - drug effects; Clinical trials; Cysts; Dietary supplements; Double-Blind Method; Exhalation - drug effects; Fatty acids; Female; Fish; Fish oils; Fish Oils - administration & dosage; Fish Oils - therapeutic use; Human performance; Humans; Hyperpnea; Inflammation; Kinesiology; Laboratories; Leukotrienes; Male; Montelukast; Nutrition; Oils & fats; pH effects; Pretreatment; Quinolines - administration & dosage; Quinolines - therapeutic use; Randomization; Respiratory Function Tests; Respiratory Medicine/Asthma; Respiratory tract; Respiratory tract diseases; Smooth muscle; Supplementation
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0013487

Both fish oil and montelukast have been shown to reduce the severity of exercise-induced bronchoconstriction (EIB). The purpose of this study was to compare the effects of fish oil and montelukast, alone and in combination, on airway inflammation and bronchoconstriction induced by eucapnic voluntary hyperpnea (EVH) in asthmatics. In this model of EIB, twenty asthmatic subjects with documented hyperpnea-induced bronchoconstriction (HIB) entered a randomized double-blind trial. All subjects entered on their usual diet (pre-treatment, n = 20) and then were randomly assigned to receive either one active 10 mg montelukast tablet and 10 placebo fish oil capsules (n = 10) or one placebo montelukast tablet and 10 active fish oil capsules totaling 3.2 g EPA and 2.0 g DHA (n = 10) taken daily for 3-wk. Thereafter, all subjects (combination treatment; n = 20) underwent another 3-wk treatment period consisting of a 10 mg active montelukast tablet or 10 active fish oil capsules taken daily. While HIB was significantly inhibited (p0.017) between treatment groups; percent fall in forced expiratory volume in 1-sec was -18.4 ± 2.1%, -9.3±2.8%, -11.6 ± 2.8% and -10.8 ± 1.7% on usual diet (pre-treatment), fish oil, montelukast and combination treatment respectively. All three treatments were associated with a significant reduction (p